BR112014028852A2 - agente para o tratamento profilático e/ou terapêutico de dor neuropática periférica causada por agente anticâncer. - Google Patents

agente para o tratamento profilático e/ou terapêutico de dor neuropática periférica causada por agente anticâncer.

Info

Publication number
BR112014028852A2
BR112014028852A2 BR112014028852-6A BR112014028852A BR112014028852A2 BR 112014028852 A2 BR112014028852 A2 BR 112014028852A2 BR 112014028852 A BR112014028852 A BR 112014028852A BR 112014028852 A2 BR112014028852 A2 BR 112014028852A2
Authority
BR
Brazil
Prior art keywords
prevention
medical treatment
peripheral neuropathy
agent
pain resulting
Prior art date
Application number
BR112014028852-6A
Other languages
English (en)
Japanese (ja)
Inventor
Kawabata
Atsufumi
Suzuki
Hideaki
Original Assignee
Asahi Kasei Pharma Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asahi Kasei Pharma Corporation filed Critical Asahi Kasei Pharma Corporation
Publication of BR112014028852A2 publication Critical patent/BR112014028852A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/366—Thrombomodulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/7455—Thrombomodulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
BR112014028852-6A 2012-05-31 2013-05-17 agente para o tratamento profilático e/ou terapêutico de dor neuropática periférica causada por agente anticâncer. BR112014028852A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2012-125316 2012-05-31
JP2012125316 2012-05-31
PCT/JP2013/063743 WO2013179910A1 (ja) 2012-05-31 2013-05-17 抗癌剤に起因する末梢性神経障害性疼痛の予防及び／又は治療剤

Publications (1)

Publication Number Publication Date
BR112014028852A2 true BR112014028852A2 (pt) 2018-04-24

Family

ID=49673113

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014028852-6A BR112014028852A2 (pt) 2012-05-31 2013-05-17 agente para o tratamento profilático e/ou terapêutico de dor neuropática periférica causada por agente anticâncer.

Country Status (21)

Country Link
US (1) US10709767B2 (pt)
EP (1) EP2857037B1 (pt)
JP (3) JP6124417B2 (pt)
KR (1) KR101672114B1 (pt)
CN (1) CN104394885B (pt)
AU (1) AU2013268725B2 (pt)
BR (1) BR112014028852A2 (pt)
CA (1) CA2875069C (pt)
DK (1) DK2857037T3 (pt)
ES (1) ES2743767T3 (pt)
HK (1) HK1203846A1 (pt)
HU (1) HUE045997T2 (pt)
IL (1) IL235984B (pt)
IN (1) IN2014DN10075A (pt)
MX (1) MX364934B (pt)
NZ (1) NZ702242A (pt)
PL (1) PL2857037T3 (pt)
PT (1) PT2857037T (pt)
RU (1) RU2595857C2 (pt)
WO (1) WO2013179910A1 (pt)
ZA (1) ZA201408769B (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ702242A (en) * 2012-05-31 2016-03-31 Asahi Kasei Pharma Corp Agent for prophylactic and/or therapeutic treatment of peripheral neuropathic pain caused by anticancer agent
JP6325036B2 (ja) * 2016-08-19 2018-05-16 株式会社明治 抗がん剤に起因する末梢神経障害を改善するための組成物
MX2019010967A (es) * 2017-03-31 2020-01-15 Toray Industries Agente terapeutico o profilactico para neuropatias perifericas.
US11628147B2 (en) 2017-12-19 2023-04-18 Synergia Life Sciences Pvt. Ltd. Vitamin K2 compositions for the treatment of drug induced neuropathy
US11497795B2 (en) 2018-09-28 2022-11-15 Asahi Kasei Pharma Corporation Medicament for mitigating conditions and/or suppressing onset of peripheral neuropathy induced by anti-malignant tumor agent
AU2019347406B9 (en) * 2018-09-28 2023-11-16 Asahi Kasei Pharma Corporation Medicament for mitigating conditions and/or suppressing onset of peripheral neuropathy induced by anti-malignant tumor agent
RU2707954C1 (ru) * 2019-01-24 2019-12-02 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации Способ лечения онкологической боли

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2738428B2 (ja) 1987-01-08 1998-04-08 旭化成工業株式会社 トロンビンによるプロテインｃの活性化を促進する作用を有するペプチド
ATE180496T1 (de) 1987-01-08 1999-06-15 Asahi Chemical Ind Peptid zur beschleunigung der wirkung des proteins-c mit thrombin
DE3876124T2 (de) 1987-04-01 1993-05-06 Mitsubishi Gas Chemical Co Immunoassay fuer thrombomodulin.
DK299087D0 (da) 1987-06-12 1987-06-12 Novo Industri As Proteins and derivatives thereof
JPS6445398A (en) 1987-08-13 1989-02-17 Kowa Co Antithrombin-binding substance monoclonal antibody, hybridoma producing said antibody and method for purifying and measuring thrombin-binding substance utilizing said monoclonal antibody
JPH0720997B2 (ja) 1988-08-29 1995-03-08 興和株式会社 新規なトロンビン結合性物質及びその製法
JPH02255699A (ja) 1989-03-28 1990-10-16 Asahi Chem Ind Co Ltd 新規血液抗凝固物質及びその製法
CA2065409C (en) 1990-06-27 2002-05-14 Mochida Pharmaceutical Co., Ltd. Anticoagulant polypeptides
JPH05213998A (ja) 1990-08-03 1993-08-24 Asahi Chem Ind Co Ltd 新規なポリペプチド及びこれを有効成分とする 医薬組成物
US5571786A (en) 1990-08-16 1996-11-05 Immuno Aktiengesellschaft Use of protein C or the activation peptide of protein C for preparing a pharmaceutical preparation
JPH05310787A (ja) 1992-05-01 1993-11-22 Asahi Chem Ind Co Ltd 新規なポリペプチド
JPH06205692A (ja) 1993-01-08 1994-07-26 Asahi Chem Ind Co Ltd 新規な抗ヒトトロンボモジュリンモノクロ−ナル抗体およびその抗体を用いたヒトトロンボモジュリンの高感度測定方法
DE69434942T2 (de) 1993-02-25 2007-11-29 Abbott Laboratories, Abbott Park Mehrzweckreagenzsystem zur schnellen lysierung von vollblutproben
JP3007785B2 (ja) 1993-03-16 2000-02-07 旭化成工業株式会社 トロンボモジュリン組成物およびその変性防止方法
EP0763360B1 (en) 1994-04-20 2005-02-16 Asahi Kasei Pharma Corporation Use of thrombomodulin for treating liver injury
JPH083065A (ja) 1994-04-20 1996-01-09 Asahi Chem Ind Co Ltd 肝臓障害に対する治療剤
US5916874A (en) 1994-04-20 1999-06-29 Asahi Kasei Kogyo Kabushiki Kaisha Method for treating liver injury
JP2824392B2 (ja) 1994-05-31 1998-11-11 旭化成工業株式会社 トロンビンによるプロテインｃの活性化を促進する作用を有するペプチドを含有する培養上澄液
US5872108A (en) 1995-03-06 1999-02-16 Interneuron Pharmaceuticals, Inc. Reduction of infarct volume using citicoline
CN1126546C (zh) 1995-03-06 2003-11-05 英特纽隆制剂药有限公司 使用胞磷胆碱减少梗塞面积
US5827832A (en) 1995-03-06 1998-10-27 Interneuron Pharmaceuticals, Inc. Method of protecting brain tissue from cerebral infarction subsequent to ischemia
JP3789147B2 (ja) 1995-04-11 2006-06-21 旭化成ファーマ株式会社 脊髄損傷後の神経障害に対する治療剤
JPH08301783A (ja) 1995-05-11 1996-11-19 Mochida Pharmaceut Co Ltd 吸収性骨疾患予防・治療剤
EP0743066A3 (en) 1995-05-16 1998-09-30 Mitsui Pharmaceuticals, Inc. Wound-healing agent
JP3931353B2 (ja) 1995-06-30 2007-06-13 持田製薬株式会社 創傷治癒剤
JP3745805B2 (ja) 1995-10-24 2006-02-15 日本ケミカルリサーチ株式会社 トロンボモジュリンの精製方法
JPH101439A (ja) 1996-06-11 1998-01-06 Mochida Pharmaceut Co Ltd 神経変性疾患治療剤
JP4157644B2 (ja) 1998-03-30 2008-10-01 旭化成ファーマ株式会社 高純度可溶性トロンボモジュリンの製造方法
WO2001072328A2 (en) 2000-03-28 2001-10-04 Eli Lilly And Company Methods of treating diseases with activated protein c
US20020111296A1 (en) 2000-08-31 2002-08-15 Festoff Barry W. Thrombomodulin analogs for use in recovery of spinal cord injury
US20060083733A1 (en) * 2002-01-18 2006-04-20 Fumihide Nishio High-concentration preparation of soluble thrombomodulin
SI1664041T1 (sl) * 2003-09-22 2008-12-31 Euro Celtique Sa Fenil-karboksamidne spojine, uporabne za tretiranje bolečine
EP1848994A2 (en) * 2005-02-16 2007-10-31 Wyeth Methods and systems for diagnosis, prognosis and selection of treatment of leukemia
US8440832B2 (en) 2007-07-13 2013-05-14 Board Of Regents, The University Of Texas System Heterocyclic modulators of cannabinoid receptors
US9394267B2 (en) 2007-07-13 2016-07-19 The Cleveland Clinic Foundation Heterocyclic modulators of cannabinoid receptors
EP2254579B1 (en) * 2008-02-18 2018-01-10 Laboratorios Del. Dr. Esteve, S.A. Use of compounds binding to the sigma receptor ligands for the treatment of neuropathic pain developing as a consequence of chemotherapy
JP2011527992A (ja) * 2008-07-16 2011-11-10 パイオン ドイチュラント ゲーエムベーハー 放射線傷害の予防および治療
TWI438009B (zh) * 2010-02-19 2014-05-21 Teikoku Pharma Usa Inc 紫杉烷前－乳劑調配物及其製造與使用之方法
JP2011178687A (ja) * 2010-02-26 2011-09-15 Kochi Univ 造血細胞移植に伴う疼痛の予防および／または治療剤
US20110287110A1 (en) * 2010-04-23 2011-11-24 Mark Wesley Dewhirst Combination cancer treatment
JP5924611B2 (ja) 2010-06-16 2016-05-25 国立大学法人高知大学 造血細胞移植に伴う生着症候群の予防及び／又は治療のための医薬
US8747844B2 (en) * 2010-07-30 2014-06-10 Saint Louis University Methods of treating pain
NZ702242A (en) * 2012-05-31 2016-03-31 Asahi Kasei Pharma Corp Agent for prophylactic and/or therapeutic treatment of peripheral neuropathic pain caused by anticancer agent

Also Published As

Publication number Publication date
DK2857037T3 (da) 2019-07-22
IN2014DN10075A (pt) 2015-08-21
RU2014148171A (ru) 2016-07-20
JP6279788B2 (ja) 2018-02-14
PL2857037T3 (pl) 2019-12-31
WO2013179910A1 (ja) 2013-12-05
US20150148296A1 (en) 2015-05-28
KR101672114B1 (ko) 2016-11-02
ZA201408769B (en) 2015-12-23
ES2743767T3 (es) 2020-02-20
HUE045997T2 (hu) 2020-01-28
US10709767B2 (en) 2020-07-14
CA2875069A1 (en) 2013-12-05
AU2013268725A1 (en) 2014-12-18
JP2017141268A (ja) 2017-08-17
HK1203846A1 (en) 2015-11-06
PT2857037T (pt) 2019-07-19
IL235984A0 (en) 2015-01-29
EP2857037A4 (en) 2016-04-06
MX2014014505A (es) 2015-06-02
EP2857037A1 (en) 2015-04-08
CN104394885B (zh) 2017-06-30
MX364934B (es) 2019-03-28
JPWO2013179910A1 (ja) 2016-01-18
CN104394885A (zh) 2015-03-04
JP2018095652A (ja) 2018-06-21
AU2013268725B2 (en) 2017-02-16
NZ702242A (en) 2016-03-31
CA2875069C (en) 2018-01-02
RU2595857C2 (ru) 2016-08-27
IL235984B (en) 2019-09-26
EP2857037B1 (en) 2019-06-26
KR20150004855A (ko) 2015-01-13
JP6124417B2 (ja) 2017-05-10
JP6427284B2 (ja) 2018-11-21

Similar Documents

Publication Publication Date Title
IL265774B (en) Diagnosis, prevention and treatment of joint diseases
HK1223246A1 (zh) 疼痛藥物組合及其用途
EP2890440A4 (en) DEVICES AND METHOD FOR THE TREATMENT OF VASCULAR DISEASES
HUE042081T2 (hu) Gyógyászati készítmény rák kezelésére és/vagy megelõzésére
EP2967484A4 (en) SYSTEM AND SIGNATURES FOR MULTIMODAL PHYSIOLOGICAL STIMULATION AND EVALUATION OF BRAIN HEALTH
EP3152321A4 (en) Diagnosis and treatment of invasive aspergillosis
BR112014028852A2 (pt) agente para o tratamento profilático e/ou terapêutico de dor neuropática periférica causada por agente anticâncer.
HK1223304A1 (zh) 包含二甲雙胍和二氫槲皮素的藥物組合及其用於治療癌症的用途
HK1211221A1 (en) Formulations for the treatment and prevention of obesity
HK1222585A1 (zh) 用於提供疼痛減輕和麻醉的二氫埃托啡
EP2962693A4 (en) PHARMACEUTICAL COMPOSITION FOR THE PREVENTION AND / OR TREATMENT OF CANCER
IL242355B (en) Cannabidiol for the prevention and treatment of graft-versus-host disease
EP2964750A4 (en) METHOD AND COMPOSITIONS FOR TREATING AND / OR PREVENTING TYPE-1 DIABETES
MX2015013755A (es) Formulacion farmaceutica para uso en el tratamiento y/o prevencion de restenosis.
IL248935A0 (en) Diagnostic testing and treatment/prevention of Alzheimer's disease
GB2537754B (en) Electronic equipment for the treatment and care of living beings
EP2949326A4 (en) MOLECULAR FIXED COMBINATION ACTIVE FOR TUMOR THERAPY AND PREVENTION
HUP1300454A2 (hu) Daganatos betegségek gyógyítására és megelõzésére alkalmas gyógyászati készítmények, és eljárás azok elõállítására
GB201301685D0 (en) Diagnosis and treatment of cancer
PL3041459T3 (pl) Kompozycje przydatne w zapobieganiu lub leczeniu raka skóry
GB201317373D0 (en) Treatment and prevention of cancer
GB201219696D0 (en) Agents for the prevention and/or treatment of central nervous system damamge

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]